AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01818583
Drug: Glucose 50 MG/ML
RxNorm normalized name: glucose 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04536363
Drug: Standard therapeutic protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard medical treatment is governed by current recommendations of national scientific societies and the Ministry of Health and Social Protection and may be modified throughout the course of the study according to the available evidence. In addition, the criteria of the treating physician are taken into account.~Among the alternatives proposed by the current clinical practice guidelines are:~1. Dexamethasone (4mg ampoule, intravenous) Dose: 6mg intravenous every day for a maximum of 10 days~2. Tocilizumab Dose: 8 mg / kg (maximum dose of 800 mg) IV, maximum 3 doses 8 to 12 hours apart~3. Empirical Antibiotic Therapy in patients with suspected pneumonia (according to management guidelines)~4. Enoxaparin (40mg prefilled syringe) Dose: 40mg subcutaneously every 24 hours~5. Enoxaparin (20mg, 40mg, 60mg, 80mg prefilled syringe) Dose: 1mg / kg every 12 hours~6. Low molecular weight heparin (5000IU prefilled syringe) Dose: 5,000 IU subcutaneous every 12 hours
Trial: NCT01780181
Drug: TCM
RxNorm normalized name: ALCOHOL 0.7 mL in 1 mL TOPICAL GEL [TCM Brand Hand Sanitizer]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TCM: In China,TCM herbs are given on the basis of the TCM syndrome differentiation as diagnosed by the TCM herbal specialist. Prescriptions formulated into granules origin from Professor Liu Jia-xiang in Longhua hospital. Package of granules is made into three types with functions such as benefiting Qi recipe, benefiting Yin recipe and detoxication and resolving masses recipe.The herbal treatment is adapted to the syndromes.
Trial: NCT01780181
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: treated with single-agent chemotherapy :DOC、NVB、GEM DOC 60mg/m2 d1 Q3W NVB 30mg/m2 d1，d8 Q3W GEM 1200mg/m2 d1，d8 Q3W
Trial: NCT01642251
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo of Veliparib
Trial: NCT01614912
Drug: SM-13496
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 or 80 mg once daily orally
Trial: NCT01792739
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo granules~: 3 gram per day (1g-1g-1g, 3 times per day)
Trial: NCT02073747
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One hour inhaled normal saline
Trial: NCT02168920
Drug: 2 mg/day
RxNorm normalized name: Neupro 2 MG/Day 24 HR Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily for 10 weeks
Trial: NCT02762032
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo supplement to take BID for 14 weeks in Arm 3
Trial: NCT03064113
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03064113
Drug: TD-4208 350 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02168920
Drug: 3 mg/day
RxNorm normalized name: Neupro 3 MG/Day 24 HR Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily for 10 weeks
Trial: NCT02168920
Drug: 6 mg/day
RxNorm normalized name: EMSAM 6 MG/Day 24HR Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily for 10 weeks
Trial: NCT02168920
Drug: Placebo (0 mg/day)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily for 10 weeks
Trial: NCT01620476
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide placebo administered to subjects randomised at each dose level in the ratio of 3:1
Trial: NCT01202760
Drug: LY2127399
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01202760
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00129675
Drug: [123I]ß CIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single Photon Emission Computed Tomography~SPECT imaging uses the single photon emissions from radioactive compounds that are (most commonly) injected into a patient and are metabolized by specific organs or body systems. SPECT imaging is performed by using a gamma camera to acquire multiple 2-D images (also called projections), from multiple angles. A computer is then used to apply a tomographic reconstruction algorithm to the multiple projections, yielding a 3-D dataset. This dataset may then be manipulated to show thin slices along any chosen axis of the body, similar to those obtained from other tomographic techniques, such as MRI, CT, and PET. The resulting SPECT images reflect body/organ function as opposed to specific anatomy of other imaging modalities such as CT or MRI.
Trial: NCT00110123
Drug: isolated perfusion
RxNorm normalized name: ISOLATE
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00541957
Drug: Medication prescribed by PCP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Can include any antidepressant medication
Trial: NCT02669173
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Drug given orally. Dose to be determined by phase 1 dose escalation, cycle length 28 days. Treatment until progression
Trial: NCT03702777
Drug: ASP8302
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Capsule
Trial: NCT03702777
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Capsule
Trial: NCT00792337
Drug: simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 mg per oral once daily for 8 weeks
Trial: NCT00792337
Drug: B1-6-12
RxNorm normalized name: vitamin B1 12.5 MG/ML Injectable Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 table per day for 8 weeks
Trial: NCT02824419
Drug: Methionine
RxNorm normalized name: Methionine
DrugBank: Methionine (DB00134)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subject undergoes imaging studies with FDG and with methionine.
Trial: NCT00294918
Drug: Serostim®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serostim® will be administered subcutaneously at a dose of 1 mg to subjects who had encountered toxicity during the antecedent protocol (Study 22388) whereas, other subjects will be randomized in 1:1 ratio, to receive either 2 milligram (mg) or 4 mg (on a weight adjusted basis) daily, starting from Day 1 of Week 1 up to Week 12 (Period 1). During Period 1, subjects who encounter toxicity will receive 1 mg Serostim® subcutaneously, daily for Period 2, starting from Day 1 of Week 13, whereas other subjects will be randomized in a 1:1 ratio to receive either 2 mg or 1 mg (on a weight adjusted basis) up to Week 36.
Trial: NCT03751566
Drug: Standard supportive therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard supportive therapy
Trial: NCT00398554
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1250 mg/m2 i.v. 60 Min.-Inf. day 1 and 21
Trial: NCT00398554
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25mg/m²/day, 2 hours i.v.infusion on day 21
Trial: NCT00290563
Drug: MK0594
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03662893
Drug: Antimuscarinic drugs used in overactive bladder
RxNorm normalized name: Sus scrofa urinary bladder preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antimuscarinic drugs (Tolterodine, solifenacin, propiverine, darifenacin,fesoterodine)
Trial: NCT00159510
Drug: Nitric oxide
RxNorm normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: An inhalation of NO via ETT at 10 ppm, partially weaned by 72 hrs of therapy
Trial: NCT00159510
Drug: Methylene blue & nitric oxide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: See the dosage in the previous arms
Trial: NCT00690560
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02567773
Drug: GSK2881078
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2881078 hot melt solutions, ranging in concentration from 0.05 mg/g to 50 mg/g, will be prepared by weighing drug substance directly into specific quantities of the hot melt vehicle solution. Subjects will be administered GSK2881078 (dose for Cohort 1: 0.75 mg for females and 1.5 mg for males) hot melt solution within capsule orally with water.
Trial: NCT02567773
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be administered as hot melt vehicle placebo within capsule orally with water.
Trial: NCT01096277
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral tablet, one per day for two weeks
Trial: NCT01954589
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00578461
Drug: Ara C
RxNorm normalized name: Toxocara cati Ab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3000 mg/m\^2 - pts will recieve via IV every 12 hours for 6 doses starting at 20:00 hours on day -8
Trial: NCT00578461
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 45 mg/kg; IV once daily on day -7 and day -6 starting at 1400 hours
Trial: NCT00412061
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A 10-mg oral daily dosing regimen (two 5-mg tablets) of matching placebo.
Trial: NCT01326754
Drug: Artemether-lumefantrine combination
RxNorm normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dispersible formulation of artemether-lumefantrine at a dose of 2/12 mg/kg body weight of artemether and lumefantrine, respectively, per dose, given twice a day for 3 days
Trial: NCT01418339
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aripiprazole-matching placebo tablet administered orally once a week.
Trial: NCT00885495
Drug: darunavir, ritonavir, rosuvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: darunavir 600 mg twice daily for 7 days ritonavir 100 mg twice daily for 7 days rosuvastatin 10 mg once daily for 7 days Combination of all three drugs for 7 days
Trial: NCT01839643
Drug: Meloxicam 2.4 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.4 g in Vaginal Ring
Trial: NCT02093143
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Target-controlled infusion of remifentanil 50 µg/ml using the pharmacologic model of Minto et al. to achieve a theorical brain concentration of 1.5 ng/ml.
Trial: NCT04565379
Drug: NuSepin® 0.1 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NuSepin® 0.1 mg
Trial: NCT04565379
Drug: NuSepin® 0.2 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NuSepin® 0.2 mg
Trial: NCT04565379
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal Saline
Trial: NCT03334136
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Five capsules the first day and thereafter one capsule every week for 4 months.
Trial: NCT01305824
Drug: PRT-201
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRT-201 10 micrograms administered at the time of AVF creation.
Trial: NCT01305824
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered at the time of AVF creation.
Trial: NCT01305824
Drug: PRT-201
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRT-201 30 micrograms administered at the time of AVF creation.
Trial: NCT02031744
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg/kg intravenous administration every 3 weeks
Trial: NCT02842827
Drug: tretinoin
RxNorm normalized name: Tretinoin
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral administration
Trial: NCT03241303
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets on experimental day.
Trial: NCT03241303
Drug: Placebo Saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9 mg/ml placebo saline infusion on experimental day.
Trial: NCT00004658
Drug: thymidine
RxNorm normalized name: Thymidine
DrugBank: Thymidine (DB04485)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00004658
Drug: uridine
RxNorm normalized name: Uridine
DrugBank: Uridine (DB02745)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00225875
Drug: Mabthéra
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00825825
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two weeks of placebo taken orally.
Trial: NCT01981772
Drug: 4% lidocaine with 1:100,000 epinephrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: see arm/group description
Trial: NCT01981772
Drug: 4% buffered lidocaine with 1:100,000 epinephrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: see arm/group description
Trial: NCT01090037
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01513967
Drug: RPh201, botanical drug product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SC administration at varying doses
Trial: NCT01513967
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SC administration at varying doses
Trial: NCT00004125
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02719197
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules matching AC-083 capsules
Trial: NCT00008047
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00004125
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02048358
Drug: 2B3-201
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02436824
Drug: AB001 patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two AB001 patches will be applied to the low back once daily for 14 days, the patches shall be removed after approximately 12 hours after daily application.
Trial: NCT00216255
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02048358
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01930240
Drug: TRIA-662
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-MNA Chloride
Trial: NCT01930240
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double-blind placebo
Trial: NCT04019561
Drug: Placebo for MEDI0382 high dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for MEDI0382 high dose administered subcutaneously
Trial: NCT04019561
Drug: Placebo for MEDI0382 low dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for MEDI0382 low dose administered subcutaneously
Trial: NCT01593735
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets, orally, once daily for 7 days
Trial: NCT02054520
Drug: HyperAcute®-Melanoma (HAM) Immunotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00349674
Drug: Azathioprine: 2 mg/kg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00349674
Drug: methotrexate 0.3 mg/kg/week, to a maximum and optimal dose of 25 mg/week
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03616977
Drug: LY900014 U-100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT04164446
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo that will be used contains starch and glucose.
Trial: NCT01856556
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single IV or PO placebo administration
Trial: NCT03427086
Drug: Biotin
RxNorm normalized name: Biotin
DrugBank: Biotin (DB00121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High dose biotin
Trial: NCT03427086
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet similar in shape and size to the biotin tablet
Trial: NCT01959477
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT03174795
Drug: RO7079901
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive RO7079901 2000 milligrams (mg) IV treatment, three times a day (TID) for up to 14 days.
Trial: NCT01125774
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match telcagepant 140 mg film coated tablet for oral administration
Trial: NCT03202875
Drug: SAR341402
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: solution~Route of administration: subcutaneous
Trial: NCT00994682
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An oral tablet identical to pioglitazone will be given once daily but without active drug for 18 months.
Trial: NCT02355704
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients were assigned to two groups, one of them received oral atorvastatin (study group) and the other, homologated placebo (control group) for 4 weeks before a kidney transplantation. Previous surgical procedure were performed
Trial: NCT00928018
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given intravenously on the first, third and sixth day after transplant
Trial: NCT00744081
Drug: AraC
RxNorm normalized name: Carac
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01205100
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02784652
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid: every 4 weeks, 6 times, 4.0 mg iv
Trial: NCT00974376
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1200mg/day of placebo for 12 weeks
Trial: NCT00231946
Drug: VP4896
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01615991
Drug: Radiosynoviorthesis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraarticular administration from 111 to 222 Mbq yttrium-90 per joint
Trial: NCT01049932
Drug: TMC278LA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TMC278LA 600mg injected intramuscularly (i/m)
Trial: NCT02447172
Drug: Gentamicin Collagen sponge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Up to 4 topical Gentamicin Collagen Sponges each containing 50 mg of gentamicin sulfate (equivalent to 32.5 mg of gentamicin base)
Trial: NCT00705861
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo as a substitute of SK3530 100mg
Trial: NCT02116868
Drug: Tailored remifentanil controlled infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The anesthesiologist in charge must adjust the peroperative remifentanil dose (Target controlled infusion) during surgery according to the algorithm proposed
Trial: NCT02731573
Drug: D-PLEX
RxNorm normalized name: Kleer Plex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-PLEX will be administered as a single application during the open heart surgery (index procedure) immediately prior to sternal closure, as an adjunct to the standard care.
Trial: NCT03226444
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One drop (approximately 50 microliters) of placebo solution will be administered three times a day (TID) to both eyes for four weeks.
Trial: NCT04412291
Drug: Standard-of-care treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SOC according to local recommendations at the Karolinska University Hospital. Oxygen supplementation so to achieve SpO2\>93%. Thrombosis prophylaxis (Fragmin or Innohep and Klexane® or new oral anticoagulants including dabigatran, apixaban or rivaroxaban).~Steroids (Betapred 6 mg po) Broad spectrum antibiotics (only in arm B and C)
Trial: NCT02866539
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Similar looking inactive powder
Trial: NCT02533570
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01455857
Drug: ITCA 650
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ITCA 650 is exenatide in DUROS
Trial: NCT01937156
Drug: SP-01 (Granisetron Transdermal Delivery System)
RxNorm normalized name: SPS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SP-01 will be applied to the upper arm 24-48 hours before the start of chemotherapy, and left in place for 7 days.
Trial: NCT01905137
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00408252
Drug: SU011248
FDA approved: no
EMA approved: no
PMDA approved: no
Description: no intervention
Trial: NCT03946657
Drug: Inhalational anesthetic
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen/air (fraction of inspired oxygen (FiO2) of 0.40), inspiratory fresh gas flow of 2 L/min), sevoflurane (1 minimum alveolar concentration \[MAC\]) and remifentanil IV infusion (0.1-0.25 mcg/kg of LBW/min) were used.Neuromuscular blockade was performed during the operation by rocuronium infusion (0.3-0.7 mg/kg of LBW/h), ensuring that PTC was zero.
Trial: NCT00758277
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar Pill